ToolGen Inc is a Korea-based company principally engaged in gene editing research and development and related businesses. The Companyâ€™s main products include patent monetization business, gene editing therapeutics, and functional seeds. The Company also operates customized gene-editing tool development services and gene analysis services. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-18	₩37,500.00	-3.23%	14,198
26-08-14	₩38,750.00	-1.40%	12,002
26-08-13	₩39,300.00	+1.68%	10,278
26-08-12	₩38,650.00	-7.87%	26,832
26-08-11	₩41,950.00	+5.14%	30,295

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. 2026-08-18			5-day change	1st Jan Change
37,500.00 ^KRW	-3.23%		-10.61%	-36.01%

05-14	ToolGen Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-12	ToolGen Incorporated Appoints Dave Boncheun Koo as New Chief Legal Officer and Executive Vice President	CI

Market Cap	337B 239M 206M 194M 176M 332M 22.88B 337M 2.28B 892M 11.45B 897M 877M 38.12B	P/E 2024	49.3x	P/E 2025	-13.8x
Enterprise Value	309B 219M 189M 178M 162M 304M 20.96B 308M 2.08B 817M 10.48B 821M 803M 34.91B	EV / Sales 2024	328x	EV / Sales 2025	380x
Free-Float	74.27%	Yield 2024 *	-	Yield 2025	-

05-14	ToolGen Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-12	ToolGen Incorporated Appoints Dave Boncheun Koo as New Chief Legal Officer and Executive Vice President	CI
11-24	Toolgen Inc. and Geneditbio Limited Enter Strategic Cross- License Agreement	CI
11-19	Toolgen completes U.S. patent registration for core CRISPR Cas9 RNP technology; files U.S. lawsuit related to Casgevy®	RE
23-11-01	ToolGen Incorporated announced that it has received KRW 33 billion in funding	CI
23-10-30	ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	CI
23-04-18	Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques	CI
23-03-23	ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-09-19	ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index	CI
22-06-15	MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc	CI
21-12-06	ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.	CI
21-09-14	ToolGen Incorporated has filed an IPO.	CI
20-12-20	ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.	CI

08-11	DNA Harvest Partners and ToolGen Announce Strategic Partnership to Accelerate AI-Guided Predictive Breeding for Gene-Edited Crops	AQ
24-12-05	ToolGen and PlantArcBio Forge Strategic Collaboration to Develop GeneEdited, Herbicide Tolerant Soybeans for Global Markets	AQ
24-04-17	The 2023 Pharmaceutical Patent Review	AQ
23-11-16	DCC Insights Issue 19	AQ
23-08-15	ToolGen Incorporated v Fisher (No 2) – Lessons In Entitlement To Priority From The Australian Federal Court	AQ

ToolGen Incorporated Stock

Stocks

A199800

KR7199800004

Biotechnology & Medical Research

Valuation: ToolGen Incorporated

Chart: ToolGen Incorporated

Latest news : ToolGen Incorporated

Press Releases: ToolGen Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: ToolGen Incorporated

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-3.23%
1 week	-10.61%
Current month	-4.58%
1 month	-13.89%
3 months	-53.12%
6 months	-27.75%
Current year	-36.01%

1 week	37,250	39,900
1 month	33,750	44,250
Current year	32,950	142,000
1 year	27,750	142,000
3 years	26,100	142,000
5 years	26,100	166,500
10 years	22,100	173,700

Manager	Title	Age	Since
Jong-Sang Yoo CEO	Chief Executive Officer	55	2025-03-27
Jang-Hyub Ha DFI	Director of Finance/CFO	49	-
Baek-Seung Lee CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jin-Soo Kim BRD	Director/Board Member	62	1999-10-07
Seong-Joon Hong BRD	Director/Board Member	61	2021-02-28
Jong-Sang Yoo BRD	Director/Board Member	55	2025-03-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/6/25	Jin-Soo Kim	Others	Founder	680,144	7.9584%
8/7/24	Lee Jaeyoung	Fiscal year		4,000	0.0504%
8/7/24	Ji-hak Han	Fiscal year		1,670	0.0210%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TOOLGEN INCORPORATED	-3.23%	-10.61%	+23.97%	+4.17%	247M
LONZA GROUP AG	-0.11%	-1.67%	+1.80%	+19.90%	48.84B
REVOLUTION MEDICINES, INC.	+1.89%	+5.08%	+492.59%	+629.24%	45.44B
BEONE MEDICINES AG	+1.83%	+2.75%	+15.61%	+91.22%	41.22B
IQVIA HOLDINGS INC.	-0.50%	-1.56%	+24.67%	+12.17%	39.71B
CELLTRION, INC.	-2.74%	-7.13%	+18.72%	+49.04%	32.6B
ASCENDIS PHARMA A/S	+0.59%	-2.25%	-	-	16.25B
MEDPACE HOLDINGS, INC.	-1.14%	-2.51%	+27.52%	+136.42%	16.67B
EUROFINS SCIENTIFIC SE	-0.49%	-0.34%	+3.45%	+29.14%	14.08B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.60%	-1.00%	+77.85%	+40.37%	13.68B
Average	-0.65%	-1.86%	+76.24%	+112.41%	26.87B
Weighted average by Cap.	-0.02%	-0.41%	+104.09%	+153.05%

	2024	2025
Net sales	891M 631K 545K 513K 466K 876K 60.45M 889K 6.01M 2.36M 30.23M 2.37M 2.32M 101M	1.31B 925K 799K 752K 683K 1.29M 88.63M 1.3M 8.82M 3.46M 44.33M 3.47M 3.4M 148M
Net income	6.23B 4.41M 3.81M 3.59M 3.26M 6.13M 423M 6.22M 42.06M 16.48M 211M 16.57M 16.21M 704M	-36.76B -26.03M -22.48M -21.15M -19.23M -36.16M -2.49B -36.69M -248M -97.25M -1.25B -97.74M -95.62M -4.16B
Net Debt	-34.94B -24.74M -21.37M -20.11M -18.27M -34.37M -2.37B -34.87M -236M -92.43M -1.19B -92.89M -90.88M -3.95B	-28.43B -20.13M -17.39M -16.36M -14.87M -27.97M -1.93B -28.38M -192M -75.21M -965M -75.58M -73.94M -3.21B